State ID: Date	of Incident Specimen Collection	n (<i>mm-dd-yyyy</i>): Surveillance Officer Initials
Form Approved OMB No. 0920-0978	CANDIDEMIA 20	24 CASE REPORT FORM
Patient name:(Last, Fir		Medical Record No.:
	st, MI)	
Address:(Number, Street, Apt. No.)		Hospital:
		Acc No. (incident isolate):
(City, State)	(Zip Code)	Acc No. (subseq isolate):
Address type: 1 ☐Residential 2 ☐Post office 3	□Long-term care facility 4 □Corr	rections 5 Military 6 Homeless 7 Other 8 Insufficient 9 Missing
Phone no.: ()		
Check if not a case:		
Reason not a case: Out of cate	chment area Duplicate entry N	Not candidemia Unable to verify address Other (specify):
SURVEILLANCE OFFICER INFO	ORMATION	
1. Date reported to EIP site:	identified through audit?	
2. Date review completed:		f yes, enter state
	- -	
DEMOGRAPHICS		
8. State ID:	10. State:	11. County:
9. Patient ID:		
12 Lah ID where positive cultur	re was identified:	
	14. Age:	
13. Date of birth (<i>mm-dd-yyyy</i>):	1 □day	
16. Weight: oz. 0 kg	17. Height: ft cm	in. OR 18. BMI: (record only if ht. and/or wt. is not available) Unknown
19. Race (check all that apply):		20. Ethnic origin:
☐American Indian/Alaska Native	□Native Hawaiian/Pac	
□Asian	□White	2 □Not Hispanic/Latino
☐Black/African American	 □Unknown	9 □Unknown
LABORATORY DATA	_	
	Collection (DISC) (mm-dd-yyyy): _	
		⁻
22. Location of Specimen Collect	tion:	
☐Hospital Inpatient	☐ Outpatient	☐ LTCF
Facility ID:	Facility ID:	Facility ID:
☐ ICU	☐ Emergency Room	☐ LTACH
☐ Surgery/OR	☐ Clinic/Doctor's office	Facility ID:
Radiology	☐ Dialysis center	☐ Autopsy
Other inpatient	☐ Surgery ☐ Observational/clinical de	☐ Other (specify):ecision unit ☐ Unknown
	Other outpatient	ecision unit Onknown
23 Candida enecies from initial	positive blood culture (check all t	that anniv):
-	positive blood cultule (Cleck dll l	
Candida albicans (CA)	☐ Candida dublinie	
Candida auris (CAU)	Candida lusitania	
☐ Candida glabrata (CG)	☐ Candida krusei (
Candida parapsilosis (CP)	☐ Candida guilliern	mondii (CGM) Pending
☐ Candida tropicalis (CT)		

Public reporting burden of this collection of information is estimated to average 40 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).

Version: Short Form 2024 Last Updated: 07/29/2023 Page **1** of **9**

		eck here 🗌 if no testing										
Date of culture	e Species	Drug	М	IC					etatio			
	1 □CA	Amphotericin B				□s []SDD	□I	□R	□NI	□ND	
	13 □CAU	Anidulafungin (Eraxis)			□s []SDD	□I	□R	□NI	□ND	
	2 □CG 3 □CP	Caspofungin (Cancidas	s)			□s [□SDD	□I	□R	□NI	□ND	
	4 □CT 5 □CD	Fluconazole (Diflucan)			□s [∃SDD	ΠI	□R	□NI	□ND	
	6 □CL	Flucytosine (5FC)				□s [□SDD	□I	□R	□NI	□ND	
	7 □CK 8 □CGM	Itraconazole (Sporano	x)			□s [∃SDD	□I	□R	□NI	□ND	
	9	Micafungin (Mycamine	e)			□s [∃SDD	□I	□R	□NI	□ND	
	11 □CS 12 □Pending	Posaconazole (Noxafil	1)			□s []SDD	□I	□R	□NI	□ND	
	12 Di chang	Voriconazole (Vfend)				□s []SDD	□I	□R	□NI	□ND	
		Amphotericin B				□s []SDD	□I	□R	□NI	□ND	
	1 □CA 13 □CAU	Anidulafungin (Eraxis)			□s []SDD	□I	□R	□NI	□ND	
	2	Caspofungin (Cancidas	s)			□s []SDD	□I	□R	□NI	□ND	
	4 □CT	Fluconazole (Diflucan)			□s []SDD	□I	□R	□NI	□ND	
	5 □CD 6 □CL	Flucytosine (5FC)				s [SDD	□I	□R	□NI	□ND	
	7 □CK 8 □CGM	Itraconazole (Sporano	x)			s []SDD	□I	□R	□NI	□ND	
	9	Micafungin (Mycamine	e)			□s [SDD		□R	□NI	□ND	
	10 □CGN 11 □CS	Posaconazole (Noxafil	1)			□s []SDD	□I	□R	□NI	□ND	
	12 Pending	Voriconazole (Vfend)				 □s []SDD		□R	□NI	□ND	
		r test for <i>Candida</i> (e.g.,										
es 0 \(\text{No} \) 9 \(\text{U} \) Fyes, test type: \(\text{Log} \) esult: \(\text{Log} \)												
ny subsequent po	sitive <i>Candida</i> blo	ood cultures in the 29 da	ays after, n	ot incl	uding t	he DIS	C? 1[□Yes	0 🗆	No 9 □]Unknov	vn
,		ositive <i>Candida</i> blood cultu	res and sele	ct the s	pecies:							
Drawn (<i>mm-dd-yy</i>)	_	s identified*		_	_	_					_	_
		□CAU □CG □CP □]CT □CD	□CL	□CK	□CGM	□co	:		□CGN	I □cs	□Pe
		□CAU □CG □CP □]CT □CD	□CL	□CK	□CGM	□co	:		□CGN	I □cs	□Pe
	□CA	□CAU □CG □CP □]CT □CD	□CL	□ск	□CGM	□co	:		□CGN	ı □cs	□Pei
	□CA	□CAU □CG □CP □]CT □CD	□CL	□ск	□CGM	□co	:		□CGN	ı □cs	□Pe

Last Updated: 07/29/2023

Page **2** of **9**

Version: Short Form 2024

State ID: Da	ate of Incident Specimen	Collection (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
		e day of or in the 29 days after the DISC (DISC)? 1 Yes 0 No 9 Unknown	(in which no blood cultures after this
27a. If yes, date of negative bloo	od culture:		
	esistant organism (MDRO	s the patient known to be colonized with () (e.g., on contact precautions)? MDROs	or being managed as if they were include CRE, CRPA, CRAB, MRSA, and VRE
28a. If yes, specify organisms (E	nter up to 3 pathogens):		
29. Additional non- <i>Candida</i> o	rganisms isolated from bl	ood cultures on the day of or in the 6 day	s before the DISC:
1 □Yes 0 □No 9 □Unkr	nown		
29a. If yes, additional organisms	(Enter up to 3 pathogens): _		
30. Did the patient have any □ □ None □ □ Unknown	of the following types of i	nfection related to their <i>Candida</i> infectio	n? (check all that apply):
☐ Abdominal infection	☐Urinary tract infection	☐Pulmonary infection	☐ Endocarditis
☐Hepatobiliary or pancreatic	☐ Esophagitis	□Abscess	Septic emboli (specify location):
☐Abscess (specify):	Oral/thrush	☐CNS infection (meningitis, brain abscess)	Other (specify):
☐Peritonitis/peritoneal fluid	Osteomyelitis	□Eyes	
□Splenic	☐Skin /wound infection	☐ Endophthalmitis	
		☐ Chorioretinitis	
MEDICAL ENCOUNTERS			
31. Was the patient hospitali	zed on the day of or in the	e 6 days after the DISC? 1 \square Yes 0	□No 9 □Unknown
31a. If yes, Date of first admission:		Unknown	
Hospital ID:	Unknow	'n	
31b. Was the patient transferred	d during this hospitalization?		
1 □Yes 0 □No 9 □Ur			
If yes, enter up to two transfers:	:		
		Unknown Date of second transfer:	Unknown
Hospital ID:			Unknown
			patient located on the 3rd calendar day befor
the DISC? (Check one)	ited prior to admission or, i	Thot currently hospitalized, where was the	patient located on the 3rd calendar day belor
1 Private residence	4 □LTAC	CH 6 □Incarcer	ated
2 Hospital inpatient	Facili	ity ID: 7 Dther (s	pecify):
Facility ID:	5 □Hom	eless 9 Unknow	n.
3 □LTCF	3 <u></u>	5 Dominion	
Facility ID:			
32. Was the patient in an ICU	I in the 14 days before, no	ot including the DISC?	
1 □Yes 0 □No 9 □U	Inknown		
33. Was the patient in an ICU	J on the day of incident sp	ecimen collection or in the 13 days after	the DISC?
	Inknown	•	
34. Did the patient receive d	ialysis or renal replaceme	nt therapy (RRT) in the 30 days before the	ne DISC, not including the DISC?
1 □Yes 0 □No 9 □U	Inknown		
35. Patient outcome: 1 □Su	rvived 9 Unknown	2 Died	
Date of discharge:		Date of death:	
	Unknown		□Unknown
Left against medical advice	(APIA)		
Version: Short Form 2024		Last Updated: 07/29/2023	Page 3 of 9

State ID: Date of	Incident Specimen Collection (mm-dd-yyyy):	Surveillance Officer Initials
35a. Discharged to: 0 □Not applicable (i.e. patient died, or 1 □Private residence 2 □LTCF Facility ID:	6	
(Check all that apply): ☐None ☐ B37 (candidiasis) Specify sub-code: Specify sub-code:	<u> </u>	where) A41.9 (sepsis, unspecified organism) R65.2 (severe sepsis)
37a. If yes, date of discharge: Facility ID: 38. Overnight stay in LTACH in the Facility ID:	e 90 days before, not including the DISC: 1 ☐Yes	0 □No 9 □Unknown
40. Underlying conditions (Checked Chronic Lung Disease Cystic Fibrosis Chronic Pulmonary disease Chronic Metabolic Disease Diabetes Mellitus With Chronic Complications Cardiovascular Disease CVA/Stroke/TIA Congenital Heart disease Congestive Heart Failure Myocardial infarction Peripheral Vascular Disease (PVD) Gastrointestinal Disease Diverticular disease Inflammatory Bowel Disease Peptic Ulcer Disease Short gut syndrome Immunocompromised Condition AIDS/CD4 count < 200 Primary Immunodeficiency Transplant, Hematopoietic Stem Celectron Transplant, Solid Organ (specify):	□ Liver Disease □ Chronic Liver Disease □ Ascites □ Cirrhosis □ Hepatic Encephalopathy □ Variceal Bleeding □ Hepatitis B, chronic □ Hepatitis C □ Treated, in SVR □ Current, chronic □ Hepatitis B, acute □ Malignancy □ Malignancy □ Malignancy, Hematologic □ Malignancy, Solid Organ (non-metastatic) □ Malignancy, Solid Organ (metastatic) □ Meurologic Condition □ Cerebral palsy □ Chronic Cognitive Deficit □ Dementia □ Epilepsy/seizure/seizure disorder □ Multiple sclerosis	□ Plegias/Paralysis □ Hemiplegia □ Quadriplegia □ Renal Disease □ Chronic Kidney Disease Lowest serum creatinine: □ Unknown or not done □ Skin Condition □ Burn □ Decubitus/Pressure Ulcer □ Surgical Wound □ Other chronic ulcer or chronic wound □ Other (specify): □ Other □ Connective tissue disease □ Obesity or morbid obesity □ Pregnant

Version: Short Form 2024 Last Updated: 07/29/2023 Page **4** of **9**

State ID: Date	of Incident Specimen Collection	n (<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
SOCIAL HISTORY			
41. Smoking (Check all that apply):		42. Alcohol Abuse:	
□None	□Tobacco	1 □Yes	
	E-nicotine delivery system	0	
		9 □Unknown	
43. Other Substances (Check all th	nat apply): None Unk	vnown	
45. Other Substances (Check all a			Mode of Delivery (Check all that apply):
☐Marijuana (other than smoking)	[DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, DEA schedule I (e.g., Hero	in) [DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, DEA schedule II-IV (e.g., r	nethadone, oxycodone)	DUD or abuse	□IDU □Non-IDU □Unknown
□Opioid, NOS	[DUD or abuse	□IDU □Non-IDU □Unknown
☐Cocaine	[□DUD or abuse	□IDU □Non-IDU □Unknown
☐ Methamphetamine		DUD or abuse	□IDU □Non-IDU □Unknown
Other (specify):		DUD or abuse	□IDU □Non-IDU □Unknown
☐Unknown substance	<u> </u>	DUD or abuse	□IDU □Non-IDU □Unknown
	_		tment (MAT) for opioid use disorder?
1 □Yes 0 □No 8 □N	/A (patient not hospitalized or did r	not have DUD) 9 □Ur	nknown
OTHER CONDITIONS			
45. For cases ≤ 1 year of age:	Gestational age at birth:v	wks 9 □Unknown ANI	D Birth weight: gms 9 Unknown
46. Chronic Dialysis: Not or	n chronic dialysis 🔲 Unknown	46a. If Hemodialysis, typ	e of vascular access:
Type: Hemodialysis Perito	neal	☐ AV fistula/graft ☐	Hemodialysis central line Unknown
47. Surgeries in the 90 days before	re, not including the DISC:	48. Pancreatitis in the	90 days before, not including the DISC:
☐Abdominal surgery (specify):		1 □Yes	
If yes: 1 ☐Open abdomen 0	□Laparoscopic 9 □Unknown	0	
□Non-abdominal surgery (specify):		9 ∐Unknown	
□No surgery			
49. Did the patient have any osto	omies of the gastrointestinal tra	act including ileostomy,	colostomy, etc. in the 30 calendar days before, not
including the DISC?			
1 □Yes 0 □No 9 □Unkno	own		
50. Chronic Urinary Tract Problem	-	50a. If yes, did the patient before, not including the	nt have any urinary tract procedures in the 90 days DISC?
1	nknown	1	9 ☐Unknown
51. Was the patient neutropenic	in the 2 calendar days before,	not including the DISC?	
1 _ '	own (no WBC days -2 or 0, or no d	_	
52. Did the patient have a CVC in	the 2 calendar days before, no	ot including the DISC?	
1 □Yes 2 □No 3 □Had C	CVC but can't find dates 9 Unk	nown	
If yes, was the central line in place	ce for > 2 calendar days: 1 \(\subseteq Yes \)	0 □No 9 □Unkr	nown
52a. If yes, CVC type: (Check all that	apply)		
□Non-tunneled CVCs	☐Implantable ports		Other (specify):
☐Tunneled CVCs	Peripherally inserted	d central catheter (PICC)	□Unknown
52b. Were all CVCs removed or change	ged in the 2 days before or in the 6	days after the DISC?	
	B ☐CVC removed, but can't find da		9 □Unknown
	5 Died or discharged before indv		
53. Did the patient have a midlin 1 ☐Yes 0 ☐No 9 ☐Unkno		ys before, not including	the DISC?

Version: Short Form 2024 Last Updated: 07/29/2023 Page **5** of **9**

State ID:	Date of Incide	nt Specimen Collection ((<i>mm-dd-yyyy</i>):	Surveillance Officer Initials
_ ·	have any of the follow	ing indwelling devices o	or other devices pres	sent in the 2 calendar days before, not including the
☐Urinary Catheter/D	evice	Respiratory		☐Gastrointestinal
☐Indwelling ure	:hral	□ET/NT		☐Abdominal drain (specify):
□ Suprapubic		☐Tracheostomy		☐Gastrostomy
		☐Invasive mecha	anical ventilation	
		CoV-2 test result (molect e the DISC or on the DI		, or other confirmatory test, excluding serology) fron
1 □Yes 0 □No	9 □Unknown			
55a. If yes, date of sp	ecimen collection for initi	al positive SARS-CoV-2 test	::	
Date: 9	☐ Date Unknown			
	ID-NET Case ID:			
		acterial medication in the	ne 14 days before, n	not including the DISC?
1 □Yes 0 □No	9 ∐Unknown			
57. Did the patient	receive any systemic s	teroids in the 30 days b	efore, not including	the DISC?
1 □Yes 0 □No	9 □Unknown			
57a. If yes, what was	the reason steroids were	administered? (check all th	hat apply)	
	given as an outpatient me			
		SC, during hospitalization a		emia episode
☐ Steroid(s)	•	/management for COVID-1	9	
58 Did the nationt	receive total narenter:	al nutrition (TPN) in the	14 days before not	t including the DISC?
1 ☐Yes 0 ☐No	-	ar natitition (TPN) in the	14 days before, flot	t including the DISC:
	-	ungal medication on the	day of or in the 13	days before the DISC?
1 ☐Yes (if Yes, fill of				
60. Was the patien	t administered systemi	c antifungal medication	after, not including	g the DISC?
1 □Yes (if Yes, fill o	<i>It question 66)</i> 0 □N	No 9 □Unknown		
61. If antifungal m	edication was not give	n to treat current candid	demia infection, wh	at was the reason?
1 □Patient died befo	re culture result available	to clinicians	5 □Other reason doc	umented in medical records, specify:
	y measures were institute		_	eatment against medical advice
	ed before culture result av		9 □Unknown	
_	ndicated culture result no			
contaminated	nuicateu cuiture result no	currically significant of		
	IF ANY A	ANTIFUNGAL MEDICATION	ON WAS GIVEN, CO	MPLETE NEXT PAGE
OTHER				
	indicate that the incide	ent specimen was consid	dered a contaminan	t or was considered to not be indicative of true
1	9 □Unknown			
		nfectious disease physic	 cian on the dav of th	he DISC or within the 6 days after the DISC?
1 □Yes 0 □No				
64. Did the patient after the DISC?	have an echocardiogra	am (ECHO), including tra	ansthoracic (TTE) or	r transesophogeal (TEE), on the day of or 13 days
1 □Yes 0 □No	9 □Unknown			
	have a dilated fundos	copic eye exam on the d	ay of or 13 days aft	er the DISC?
65. Did the patient	nave a unateu runuost		-	
65. Did the patient 1 □Yes 0 □No				

Version: Short Form 2024 Last Updated: 07/29/2023 Page **6** of **9**

photericin – licet, AmBio dulafungin (ons (NOTE: Please use abbreviation any IV formulation (Amphotec, Amphocsome, etc.)=AMBIV Eraxis)=ANF ancidas)=CAS	l, Fungizone, Fl Fl Is Itı	uconazole (Diflucan)=FLC ucytosine (5FC)=5FC avuconazole (cresemba)=ISU raconazole (Sporanox)=ITC icafungin (Mycamine)=MFG	Po UN	her=OTH saconazole (Noxafil)=PSC IKNOWN DRUG=UNK riconazole (Vfend)=VRC	
ANTIFUNG a. Drug Abbrev	b. First date given (mm-dd-yyyy)	c. Date start unknown	d. Last date given (mm-dd-yyyy)	e. Date stop unknown	f. Indication	g. Reason for stoppin (if applicable)*
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
	-				Prophylaxis Treatment	
					Prophylaxis Treatment	
	-				Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	
					Prophylaxis Treatment	

State ID: ______ Date of Incident Specimen Collection (mm-dd-yyyy): ___-___ Surveillance Officer Initials _____

Version: Short Form 2024 Last Updated: 07/29/2023 Page **7** of **9**

State ID:	Date of I	ncident Specimen Collection	on (<i>mm-dd-yy</i>)	yy): Surveillance Officer Initials
		AFST results for a	additional (Candida icolatos
Antifungal suscenti	ihility testing (ch	eck here if no testing do		
Date of culture	Species	Drug	MIC	Interpretation
	1 □CA	Amphotericin B		□S □SDD □I □R □NI □ND
	13 □CAU	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	2 □CG 3 □CP	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	4 □CT	Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND
	5 □CD 6 □CL	Flucytosine (5FC)		□S □SDD □I □R □NI □ND
	7 □CK	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	8	Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	9 □CO 10 □CGN	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	11 □CS 12 □Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
		Amphotericin B		□S □SDD □I □R □NI □ND
	1 □CA 13 □CAU	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	2 □CG	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	3 □CP 4 □CT	Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND
	5 □CD	Flucytosine (5FC)		□S □SDD □I □R □NI □ND
	6 □CL 7 □CK	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	8 □CGM	Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	9	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	11 CS 12 Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
Intifungal suscepti		eck here \square if no testing do	one/no test re	ports available):
Date of culture	Species	Drug	MIC	Interpretation
	1 □CA	Amphotericin B		□S □SDD □I □R □NI □ND
	13 □CAU 2 □CG	Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	3 □CP	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	4 □CT 5 □CD	Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND
	6 □CL	Flucytosine (5FC)		□S □SDD □I □R □NI □ND
	7 □CK 8 □CGM	Itraconazole (Sporanox)		□S □SDD □I □R □NI □ND
	9 □CO	Micafungin (Mycamine)		□S □SDD □I □R □NI □ND
	10 □CGN	Posaconazole (Noxafil)		□S □SDD □I □R □NI □ND
	11 □CS 12 □Pending	Voriconazole (Vfend)		□S □SDD □I □R □NI □ND
	1 □CA	Amphotericin B		□S □SDD □I □R □NI □ND
		Anidulafungin (Eraxis)		□S □SDD □I □R □NI □ND
	13 □CAU			
	2 □CG	Caspofungin (Cancidas)		□S □SDD □I □R □NI □ND
	2 □CG 3 □CP 4 □CT			☐S ☐SDD ☐I ☐R ☐NI ☐ND ☐S ☐SDD ☐I ☐R ☐NI ☐ND
	2 □CG 3 □CP 4 □CT 5 □CD	Caspofungin (Cancidas)		
	2 □CG 3 □CP 4 □CT	Caspofungin (Cancidas) Fluconazole (Diflucan)		□S □SDD □I □R □NI □ND
	2 □CG 3 □CP 4 □CT 5 □CD 6 □CL	Caspofungin (Cancidas) Fluconazole (Diflucan) Flucytosine (5FC)		☐S ☐SDD ☐I ☐R ☐NI ☐ND ☐S ☐SDD ☐I ☐R ☐NI ☐ND

State ID:	Date of In	cident Specimen Colle	ection (<i>mm-dd-yy</i>	<i>(YY</i>):		Survei	llance	Officer	Initials	
	10 □CGN 11 □CS 12 □Pending	Voriconazole (Vfend)			S□SDD	ΠI	□R	□NI	□ND	
Version: Short	t Form 2024	La	st Updated: 07/29/	/ 2023					Page 9 of 9	